Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S.

Order of cancer-driving mutations affects the chance of tumor development, study shows

The order of cancer-driving mutations—genetic changes—plays an important role in whether tumors in the intestine can develop, ...
TipRanks on MSN

Incyte announces FDA granted breakthrough therapy designation to INCA033989

Incyte (INCY) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy designation to INCA033989, a ...
JSTOR Daily

Tissue-Specific Transformation by Epidermal Growth Factor Receptor: A Single Point Mutation within the ATP-Binding Pocket of the erbB Product Increases its Intrinsic Kinase ...

Proceedings of the National Academy of Sciences of the United States of America, Vol. 87, No. 23 (Dec., 1990), pp. 9103-9107 (5 pages) Avian c-erbB is activated to a leukemia oncogene following ...
ascopubs.org

Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors.

Role of chest radiation in extensive-stage small cell lung cancer with ipsilateral pleural effusion. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not ...
Everyday Health

Gene Mutation CHEK2 and Cancer Risk

Checkpoint kinase 2, or CHEK2, for short, is a gene that normally helps with DNA repair. If you have a mutation, or variation, in this gene, you may be at an increased risk for developing cancer. The ...